LI
LIC MF Flexi Cap Fund Direct Growth
Latest NAV
+0.71% 1Y
Sign In to Add to Portfolio
Benchmark: Nifty 500 TRI
Expense ratio
1.95%
AUM
₹1,125 Cr
Min SIP
₹200
Min lump sum
₹5,000
1Y
+0.71%
3Y (ann.)
+9.87%
5Y (ann.)
+9.37%
Launched
Jan 2013
Where the NAV sits & how risky it is
₹112.17
52-week range
at 62%
₹112.17
Low 23 Mar 2026₹96.20
High 31 Aug 2026₹122.16
Risk level
Very High
Low
Very high
NAV history
02 Jan 2013
Since inception
05 Oct 2026
Returns by period
1W
-2.94%
1M
-7.57%
3M
-2.71%
6M
+13.32%
1Y
+0.71%
3Y
+9.87%
5Y
+9.37%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹200
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 97.49%
Cash & other 4.71%
Sector split
Country split
Top 5 hold 20.4%
Top 10 hold 35.1%
50 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | ICICI Bank
INE090A01021 |
Financial Services Banks - Regional |
India |
6.35%
|
-6.90% |
| 2 | Axis Bank
INE238A01034 |
Financial Services Banks - Regional |
India |
4.03%
|
-0.10% |
| 3 | Larsen & Toubro
INE018A01030 |
Industrials Engineering & Construction |
India |
3.43%
|
-4.16% |
| 4 | Solar Industries
INE343H01029 |
Basic Materials Specialty Chemicals |
India |
3.29%
|
+47.85% |
| 5 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
3.24%
|
+18.83% |
| 6 | Navin Fluorine International
INE048G01026 |
Basic Materials Chemicals |
India |
3.15%
|
+15.94% |
| 7 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
2.97%
|
+15.54% |
| 8 | Hitachi Energy
INE07Y701011 |
Industrials Electrical Equipment & Parts |
India |
2.89%
|
+91.21% |
| 9 | Interglobe Aviation
INE646L01027 |
Industrials Airlines |
India |
2.87%
|
-13.83% |
| 10 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
2.86%
|
+4.66% |
About this scheme
The main investment objective of the scheme is to provide capital growth by investing across Large, Mid & Small Cap stocks. The investment portfolio of the scheme will be constantly monitored and reviewed to optimise capital growth. However, there is no assurance that the investment objective of the Schemes will be realized.
Fund manager(s): Sudhanshu Asthana, Nikhil Kapoor
Exit load: Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 3 months.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
01 Jan 2013
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 120.8 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 32.7 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 29.9 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 29.9 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 28.5 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 28.4 pts ahead of this fund